AOD-9604, which is also known as Tyr-hGH Frag 176-191, is a modified version of the hGH fragment 176-191 peptide. This peptide is derived from human growth hormone (hGH) and contains a disulfide bridge.
Originally created as a lipolytic compound for treating obesity, AOD-9604 has demonstrated potential in animal studies for treating heart disease, osteoarthritis, and metabolic syndrome by promoting cartilage repair and fat breakdown while inhibiting fat creation.
Studies have indicated that AOD-9604 can stimulate lipolysis without affecting insulin or IGF1 levels, suggesting that it may not lead to the development of diabetes or glucose intolerance. Furthermore, since it shares structural similarities with HGH, it is less likely to cause immunogenic reactions, making it a promising treatment candidate that is safe to study.
AOD-9604 has demonstrated potent lipolytic activity without impacting glucose levels, tissue growth, or inducing overeating.
Unlike hGH, AOD-9604 has a distinct mechanism of action that activates fat degradation and oxidation through means independent of the hGH receptor. Through laboratory experimentation on various animals, including rodents, pigs, dogs, and humans, the unique mechanism of AOD-9604 has been identified, which primarily stimulates the release of fat from adipose tissue, inhibits the accumulation of new fat in adipocytes, and promotes fat oxidation. AOD-9604 is particularly remarkable for its ability to decrease fat stores in the abdominal region.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
AOD-9604 is a high-purity research peptide derived from the C-terminal fragment of human growth hormone (hGH 176–191). It is engineered for controlled laboratory investigation of lipid metabolism, energy expenditure pathways, and adipose tissue signaling. Each vial of AOD-9604 is synthesized to research-grade standards and undergoes rigorous analytical testing to support reproducible, protocol-driven experimental design.
AOD-9604 Research Peptide Specifications:
| Unit Size | 5 mg/vial |
| Unit Quantity | 1 vial |
| Purity (HPLC) | > 99% |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| Molecular Formula | C78H123N23O23S2 |
| Molecular Weight | ≈ 1815.1 g/mol |
| CAS Number | 221231-10-3 |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage Conditions | Lyophilized AOD-9604 should be stored at −20 °C or below, protected from light and moisture. Reconstituted solutions should be stored at 2–8 °C and used promptly for in vitro and in vivo animal research, following institutional guidelines. |
| Research Use Only | This peptide is supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. Please review all terms and conditions prior to purchase. |
AOD-9604 is a synthetic peptide fragment corresponding to the 176–191 region of human growth hormone, extended with an N-terminal tyrosine. Preclinical models indicate that this fragment retains the lipolytic and anti-lipogenic signaling properties of native hGH while minimizing broader growth hormone–related effects.
In animal studies, AOD-9604 has been investigated for its impact on adipocyte lipid turnover, beta-adrenergic receptor expression, and energy expenditure. Chronic administration in obese mouse models has been associated with changes in body weight, fat mass, and β3-adrenergic receptor mRNA expression, supporting its use as a tool compound for dissecting adipose tissue signaling networks.
Beyond direct effects on adipocytes, AOD-9604 has been evaluated in toxicology and pharmacokinetic studies across multiple species, including rodents, pigs, and non-human primates. These studies provide insight into systemic distribution, rapid peptide degradation, and oral versus parenteral exposure profiles, and are frequently referenced when designing contemporary preclinical research protocols.
Importantly, while AOD-9604 has been studied in the context of obesity and metabolic health, it is not approved by the U.S. Food and Drug Administration (FDA) for weight loss or any therapeutic indication. Regulatory agencies have emphasized that AOD-9604 remains an investigational compound, reinforcing its role as a research-only peptide.
Important Research Notice: Nordsci peptides are supported by independent third-party analytical testing to validate identity and purity via HPLC and mass spectrometry. A Certificate of Analysis (COA) is available for each lot to help labs align with internal quality management and documentation requirements.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Preclinical studies have shown that AOD-9604 can modulate lipid metabolism in obese mouse models, including effects on body fat, lipolysis, and beta-adrenergic signaling. In one frequently cited study, chronic AOD-9604 administration altered β3-adrenergic receptor expression in adipose tissue, providing a mechanistic framework for exploring adipocyte responsiveness and energy mobilization in obesity research.
These findings position AOD-9604 as a useful probe for investigating the interface between growth hormone fragments, adrenergic pathways, and downstream lipid handling across different fat depots.
AOD-9604 has been evaluated in models that track changes in energy expenditure, substrate utilization, and thermogenesis. Data from obese and β3-adrenergic receptor knockout mice suggest that the peptide can influence energy expenditure and fat oxidation independently of direct β3-receptor agonism, making it a candidate for studying non-classical pathways of metabolic activation.
Researchers frequently integrate AOD-9604 into broader metabolic protocols that measure body mass, indirect calorimetry endpoints, and transcriptional changes in key metabolic tissues.
Comprehensive toxicology programs have investigated AOD-9604 across rats, pigs, and non-human primates, examining clinical chemistry, organ histopathology, and potential mutagenicity endpoints. Long-term dosing studies (up to several months) have reported rapid plasma clearance, high first-pass metabolism, and limited accumulation, with no major toxicological red flags at tested research doses.
These datasets are frequently used to design new animal protocols, particularly when researchers seek to understand exposure–response relationships, peptide degradation kinetics, or tissue distribution patterns relevant to metabolic and endocrine research.
Within experimental frameworks, AOD-9604 is sometimes studied alongside other metabolic peptides or small molecules to evaluate potential synergy or pathway complementarity. In these models, investigators typically focus on endpoints such as adipocyte turnover, hepatic lipid handling, and endocrine markers that collectively define the metabolic phenotype.
All such applications remain strictly preclinical. Any discussion of “weight loss” in the literature refers to animal and in vitro research endpoints, not validated clinical outcomes in humans.
Each lot of AOD-9604 is supported by a detailed Certificate of Analysis documenting peptide identity, purity, and analytical methods used (HPLC, mass spectrometry, and related assays as applicable). COA documentation is supplied with qualifying orders and can be obtained from Nordsci customer support for protocol files, regulatory submissions, or internal quality audits.
Sourcing AOD-9604 for institutional use requires partnering with suppliers that maintain robust quality systems and transparent analytical documentation. Nordsci Peptides focuses on providing high-purity, research-grade peptides with consistent lot-to-lot performance and clear labeling for laboratory applications.
How to Source AOD-9604 for Laboratory Research
When selecting a supplier, laboratories should verify that each batch of AOD-9604 includes clear labeling, batch/lot identifiers, COA access, and validated purity data. This level of documentation helps research teams align with internal SOPs, GLP-style practices, and ethics or compliance committee expectations.
AOD-9604 Research Peptide Pricing Considerations
Research-grade AOD-9604 pricing is typically driven by unit size, synthesis complexity, purity targets, and the depth of analytical testing performed. Many institutions account not only for per-milligram cost, but also for the compliance value of strong documentation and stable supply when budgeting for multi-phase or multi-cohort studies.
Research Institution Procurement and Compliance
Procurement teams should ensure that AOD-9604 is purchased exclusively for non-clinical use under documented research protocols. Storage, handling, and inventory records should be maintained in alignment with internal quality procedures to support data integrity and regulatory readiness.
IMPORTANT: AOD-9604 is sold exclusively for in vitro and preclinical research applications. It is not approved for human use, weight-loss treatment, or any therapeutic purpose. Researchers are responsible for complying with all applicable regulations and institutional policies governing peptide research in their jurisdiction.
